Journal of Blood & Lymph

ISSN: 2165-7831

Open Access

Shimon Slavin

International Center for Cell Therapy and Cancer Immunotherapy (CTCI),
Tel Aviv 64239

  • Review
    Towards Possible Cure of Cancer by Immunotherapy of Minimal Residual Disease
    Author(s): Shimon Slavin, Nadir Askenasy and Chaya BrodieShimon Slavin, Nadir Askenasy and Chaya Brodie

    Based on predictive, preventive and personalized medicine (PPPM) strategy for treatment of cancer, immunotherapy and additional targeted anti-cancer modalities should be considered for cure of cancer at an early stage of the disease following successful conventional treatment. Alternatively, PPPM strategy should be applied at the stage of minimal residual disease (MRD) induced following successful re-induction of second or subsequent remission.Fortunately, a stage of minimal residual disease can be accomplished in most patients with cancer following conventional treatment but in the absence of visible disease or lack of symptoms, additional treatment is usually denied. Considering PPPM using innovative and safe treatment focusing on immunotherapy should be considered for patients at risk because eradication of MRD can be accomplished whereas treatment of overt disease may no lon.. Read More»
    DOI: 10.4172/2165-7831.1000137

    Abstract PDF

Relevant Topics

Google Scholar citation report
Citations: 443

Journal of Blood & Lymph received 443 citations as per Google Scholar report

Journal of Blood & Lymph peer review process verified at publons

Indexed In

arrow_upward arrow_upward